...
首页> 外文期刊>Oncology reports >MicroRNA-101 regulates T-cell acute lymphoblastic leukemia progression and chemotherapeutic sensitivity by targeting Notch1
【24h】

MicroRNA-101 regulates T-cell acute lymphoblastic leukemia progression and chemotherapeutic sensitivity by targeting Notch1

机译:MicroRNA-101通过靶向Notch1来调节T细胞急性淋巴细胞白血病的进展和化疗敏感性

获取原文
获取原文并翻译 | 示例

摘要

The present study aimed to investigate the role of microRNA (miR)-101 in acute lymphoblastic leukemia progression and chemoresistance. Furthermore, a novel target gene of miR-101 was identified. Here, we confirmed that miR-101 was significantly downregulated in the blood samples of patients with T-cell acute lymphoblastic leukemia (T-ALL) compared with the healthy controls, as determined by reverse transcription quantitative polymerase chain reaction (RTqPCR) analysis. The in vitro experiments demonstrated that miR-101 significantly repressed the proliferation and invasion, and induced potent apoptosis in Jurkat cells, as determined by CCK-8, flow cytometer and cell invasion assays. Luciferase assay confirmed that Notch1 was a target gene of miR-101, and western blotting showed that miR-101 suppressed the expression of Notch1 at the protein level. Moreover, functional restoration assays revealed that Notch1 mediates the effects of miR-101 on Jurkat cell proliferation, apoptosis and invasion. miR-101 enhanced the sensitivity of Jurkat cells to the chemotherapeutic agent adriamycin. Taken together, our results show for the first time that miR-101 acts as a tumor suppressor in T-cell acute lymphoblastic leukaemia and it could enhance chemotherapeutic sensitivity. Furthermore, Notch1 was identified to be a novel target of miR-101. This study indicates that miR-101 may represent a potential therapeutic target for T-cell acute lymphoblastic leukemia intervention.
机译:本研究旨在研究microRNA(miR)-101在急性淋巴细胞白血病进展和化学耐药性中的作用。此外,鉴定了miR-101的新靶基因。在这里,我们证实与逆转录定量聚合酶链反应(RTqPCR)分析相比,与健康对照组相比,T细胞急性淋巴细胞白血病(T-ALL)患者的血液样本中miR-101显着下调。体外实验表明,miR-101可以显着抑制Jurkat细胞的增殖和侵袭,并通过CCK-8,流式细胞仪和细胞侵袭试验测定其诱导的有效凋亡。荧光素酶测定证实Notch1是miR-101的靶基因,蛋白质印迹显示miR-101在蛋白质水平上抑制了Notch1的表达。此外,功能恢复测定显示Notch1介导miR-101对Jurkat细胞增殖,凋亡和侵袭的影响。 miR-101增强了Jurkat细胞对化疗剂阿霉素的敏感性。两者合计,我们的结果首次表明miR-101在T细胞急性淋巴细胞白血病中起着抑癌作用,并且可以增强化疗敏感性。此外,Notch1被确定为miR-101的新型靶标。这项研究表明,miR-101可能代表T细胞急性淋巴细胞白血病干预的潜在治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号